Abstract The accuracy of cytogenetic analyses of human solid cancers has improved enormously over the past decade by the introduction and refinement of DNA in situ hybridization (ISH) techniques. This methodology can be applied to cells in the interphase state, thereby making it an excellent tool for the delineation of chromosomal aberrations in solid tumors. The use of non-isotopic ISH to intact and disaggregated cancer specimens will be discussed, as well as comparative genomic hybridization (CGH) with tumor-derived DNAs. In this review we will focus on hybridocytochemical interphase approaches for the detection of chromosomal changes in frequently occurring human epithelial malignancies, e.g., breast, lung, and prostate carcinomas. We will further discuss the use of ISH procedures for the genetic analysis of precursor conditions leading to invasive carcinomas. Knowledge concerning these precancerous conditions is increasing, and its importance in cancer prevention has been recognized. Interphase cytogenetics by ISH, as well as CGH, with DNAs derived from microdissected, precancerous, dysplastic tissue areas will increase our understanding of these lesions, both at the investigative and diagnostic levels.& b d y :
Introduction
In 1914, Theodor Boveri concluded in his classical work entitled ''Zur Frage der Entstehung maligner Tumoren'' that cancer is a genetic disease, caused by clonal chromosomal changes (Boveri 1914) . Most of Boveri's statements eventually turned out to be true. However, it was not until 1960 that the first consistent chromosomal abnormality was found in human tumor cells [i.e., the Philadelphia (Ph) chromosome in chronic myelogenous leukemia; Nowell and Hungerford 1960] . With the subsequent introduction and continuous improvement of chromosome banding techniques, allowing reliable recognition of each chromosome and of sub-chromosomal structures, a large-scale search for specific karyotypic abnormalities could be initiated. Initially, most information was obtained from leukemia and lymphoma (Sandberg 1990) . In two decades a vast amount of detailed information on the occurrence of chromosomal abnormalities in human cancer has been accumulated (see Sandberg 1990; Mitelman 1994 for reviews) and acquired clonal chromosomal aberrations have indeed been demonstrated to be a characteristic feature of tumor cells (Nowell 1976; Heim and Mitelman 1987; Sandberg 1990) . The general view is that tumor initiation and progression is a multistep process, caused by an accumulation of genetic aberrations resulting in the activation of oncogenes and/or inactivation of tumor suppressor genes (Knudson 1971; Vogelstein et al. 1988 ; reviewed by Bishop 1991) . In the last decade, precancerous lesions, such as large bowel adenomas or cervical dysplasias, have attracted much attention for their role in malignant transformation to invasive cancer (Rosai 1996) . These precursor lesions have currently established their importance in cancer prevention and surveillance.
In situ hybridization and comparative genomic hybridization of epithelial neoplasms metaphases is relatively poor. Therefore, interphase approaches, both at molecular and cytological levels, are better equipped to disclose genetic changes occurring in human epithelial cancers (Table 1) and their precursor lesions (Table 2 ) (see also Alers and van Dekken 1996, and references therein) . In this section we will review the literature concerning interphase DNA in situ hybridization (ISH), also termed interphase cytogenetics, as well as comparative genomic hybridization (CGH) of frequently occurring human epithelial neoplasms. In Figs. 1-3, examples (esophageal and prostatic cancer) are shown of ISH ( Fig. 1) and CGH ( Fig. 2 ) of invasive cancers and their precancerous conditions (Fig. 3) .
Lung cancer
In the literature, a subdivision is often made between small cell lung cancers (SCLCs) and non-small cell lung cancers (NSCLCs), the latter comprising squamous cell carcinoma and adenocarcinoma. Interphase cytogenetics on paraffin sections of lung tumors by non-isotopic ISH Table 1 Genetic alterations in frequently occurring human epithelial cancers (Alers and van Dekken 1996) . (LOH Loss of heterozygosity, ISH in situ hybridization, CGH comparative genomic hybridization, SCLC small cell lung cancer, NSCLC non-small cell lung cancer, i isochromosome)& / t b l . 
was also performed by Kim et al. (1993) . ISH data were found to correlate with the DNA index, derived from image analysis of Feulgen-stained nuclei. However, in some cases, chromosome 7 or 17 was either over-or underrepresented compared with the DNA index. Fluorescence ISH (FISH) analysis of a SCLC cell line elucidated the origin of homogeneously staining regions (HSRs; Dietzsch et al. 1994) . These authors found the amplified region to contain the N-myc gene. Recently, the copy number of p15 and p16/MTS1, both located at 9p21-p22, was determined by double-color FISH analysis of cell suspensions of 18 primary NSCLCs, using a P1 (phage) contig probe (Xiao et al. 1995) . Co-deletion of p15 and p16 was found in 15 of 18 NSCLCs. It was concluded that p15 and p16 are deleted and/or mutated in most primary NSCLCs. A CGH study of 13 primary SCLCs was performed by Ried et al. (1994) . Losses of chromosome arms 3p, 5q, 10q, 13q, and 17p were detected, as well as DNA gains of 3q, 5p, 8q, and 17q. The most frequently amplified site was 19q13.1. Further, a CGH study of SCLC cell lines by Levin et al. (1994) revealed increases in DNA sequences at regions 1p22 (L-myc), 2p24-p25 (Nmyc), 5p, 8q24 (c-myc), and Xq26. Decreases were found at 3p, 10q26, 13q14 (Rb) 16p11, 17p13 (p53), and 22q12-q13. The results, described above, were confirmed in recent investigations on larger panels of tumors Petersen et al. 1997 ).
Head and neck cancer
Head and neck tumors consist mostly of squamous cell carcinomas (HNSCCs). Numerical aberrations of chromosome 17 were investigated in cell suspensions, derived from four oral tumors, by FISH with centromeric probes Y and aneuploidy for chromosome 1 reached high prevalences in high-grade dysplasia and adenocarcinoma. Hunter et al. (1993) 
Colorectal cancer
Colorectal adenocarcinomas arise, in general, in adenomatous polyps. Cajulis and Frias-Hidvegi (1993) showed gain of chromosome 8 in one out of three fine-needle aspirates from colon adenocarcinomas. FISH applied to single-cell suspensions of 35 colonic adenomas revealed trisomy of chromosome 7 in over one-third of cases (Herbergs et al. 1994) . In nearly half of the cases, this aberration was combined with abnormalities of the other chromosomes investigated. ISH applied to 23 archival advanced stage colon cancer specimens, revealed three to eight copies of chromosomes 8, 12, and 17 (Steiner et al. 1993) . The mean frequency of multiple copies for chromosome 12 was significantly greater than that for chromosome 17. Chen and Nierman (1994) used chromosome painting by FISH with library probes to examine abnormalities identified by G-banding in two colon cancer cell lines, DLD-1 and HCT-15. Trisomy of chromosome 20 and trisomy of the 2p13-p23 segment were seen in the DLD-1 cell line, whereas in HCT-15, a t(16;16) and gain of Y were seen. Recently, Sasaki et al. (1995) demonstrated monosomy of chromosome 18 in one-third of cases using FISH on suspensions derived from early carcinomas without foci of adenoma. Suspensions derived from more advanced cancers showed monosomy 18 in 44% of cases. In addition to these ISH data, CGH revealed gain of chromosomes 7, 13, and 20q, whereas loss was seen of 9p, 17, and 18 (Schlegel et al. 1995) . Ried et al. (1996) identified gain of 7 in low-grade adenomas, whereas in high-grade adenomas gain of chromosome 20 also occurred. Further, the transition from adenoma to carcinoma was characterized by multiple additional alterations, such as loss of 18q or gain of 8q.
Prostate cancer
The vast majority of prostatic cancers are adenocarcinomas. Many studies have been reported concerning (F)ISH to nuclear suspensions and paraffin sections of prostatic cancer. Numerical aberrations of chromosomes 7, 8, 10, 16, 17, 18, and Y were revealed (van Dekken et al. 1990b; van Dekken and Alers 1993; Baretton et al. 1994; Brown et al. 1994; Henke et al. 1994; Jones et al. 1994; Visakorpi et al. 1994; Zitzelsberger et al. 1994; Alers et al. 1995a) . Furthermore, FISH studies of nuclear suspensions or touch imprints of prostatic tumors revealed that 423 (Tsuji et al. 1994) . The copy number of chromosome 17 significantly increased in oral malignant tumors compared to benign tumors. Worsham et al. (1995) demonstrated rearrangements of Y and aneuploidy in two synchronously arising primary squamous cell carcinomas (SCCs) and their recurrences. Moreover, these authors concluded that the FISH patterns and the presence of a clonal Y marker in all four tumor samples indicate a monoclonal origin of the synchronous primaries and their recurrences. Recently, Lese et al. (1995) visualized INT2 and HST1 amplification in oral SCCs, containing HSRs, by dual-color FISH with cosmid probes specific for the chromosome 11q13 region. Non-isotopic ISH on paraffin-embedded tissue sections of 25 HNSCCs using centromere probes specific for chromosomes 7 and 17, revealed polysomy in both premalignant and tumor tissue (Voravud et al. 1993) . Moreover, the frequency of cells with polysomy increased as the tissues passed from histologically normal epithelium to hyperplasia to dysplasia to cancer.
A CGH analysis of 13 primary HNSCCs by Speicher et al. (1995) showed a frequent copy number increase on chromosome regions 3q and 5p and less frequently on 1q. Loss occurred most frequently at 3p, 5q, 19p, and 19q. Eight sites exhibiting sequence amplification were mapped to 3q26-qter, 11q13, 12p, 2q33-q36, 7q21-q22, 7q33-qter, 9p, and 13q23-qter. The authors suggest that the regions 3q26-qter and 5p may harbor oncogenes important in HNSCC development. A CGH study by Brzoska et al. (1995) of ten HNSCCs also identified gain of the chromosome 3q26-q27 region and loss of chromosome 3p at high frequency (over 50% of cases). These findings were largely confirmed in a recent study of 30 HNSCCs (Bockmuhl et al. 1996) . However, in addition to these changes, frequent losses were seen of 1p, 8p, 9p, and 13q, as well as frequent gains of 8q and 19.
Esophageal cancer
In the esophagus, the incidence of adenocarcinoma is increasing rapidly, now equalling that of SCC. Most esophageal adenocarcinomas arise in so-called Barrett's epithelium, a precancerous lesion near or at the gastro-esophageal junction. ISH applied to archival tissue sections of 14 adenocarcinomas of the esophagus using three chromosome Y-specific DNA probes showed absence of the Y chromosome in 93% of the adenocarcinomas (Hunter et al. 1993) . FISH on nuclear suspensions of ten gastric adenocarcinomas also revealed loss of the Y chromosome in a high percentage of male patients (van Dekken et al. 1990a ). In a study by our group of four archival adenocarcinomas, loss of the Y chromosome, overrepresentation of chromosome 8, and loss of chromosome 17 were observed. In two tumors, negative for p53 protein immunohistochemistry, loss of 17 was found (Krishnadath et al. 1994) . In another study, aneuploidy, as determined by ISH for chromosome 1, and loss of Y correlated with progression from metaplasia to dysplasia to carcinoma (Krishnadath et al. 1995) . Loss of alterations of chromosomes 7 and 8 are potential markers of poor prognosis in prostate cancer Bandyk et al. 1994; Takahashi et al. 1994) . A combined ISH and CGH analysis showed that gain of chromosome 8 was, generally, based on isochromosome 8q formation (J.C. Alers et al., submitted for publication). Deletion of 8p22 sequences was seen by FISH with cosmid DNA probes (Matsuyama et al. 1994a ). Likewise, Macoska et al. (1994) showed loss of 8p22 sequences in frozen tissue sections of prostatic tumors by FISH. Further, intratumoral heterogeneity for both ploidy and chromosomal aberrations appeared a prominent feature of prostatic adenocarcinomas (Alers et al. 1995b) . Another study by our group described aneuploidy and loss of the Y chromosome in prostatic intraepithelial neoplastic lesions adjacent to adenocarcinoma (Alers et al. 1995a) .
A CGH study by Cher et al. (1994) demonstrated loss of 8p sequences in a panel of 17 prostatic tumors. Further, 8p loss and 8q gain as detected by CGH correlated with allelic imbalance mapping by a PCR/RFLP study. A subsequent investigation by the same group (Cher et al. 1996 ) on a panel of regional lymph node and bone metastases showed frequent gain of 8q, as well as loss of 8p, 10q, 13q, 16q, and 17p. Furthermore, a CGH study of 31 primary and 9 recurrent prostatic carcinomas by Visakorpi et al. (1995a) revealed losses of 6q, 8p, 9p, 13q, 16q, and 18q. Allelic loss studies showed a 76% concordance with CGH results. Local recurrences that developed during endocrine therapy showed significantly more gains and losses of DNA sequences than primary tumors. Gains of 8q, X, and 7, as well as loss of 8p were particularly involved. Comparable changes were observed by Joos et al. (1995) . CGH also revealed that amplification of the chromosome X-linked androgen receptor gene commonly occurs in recurrent tumors during androgen deprivation therapy (Visakorpi et al. 1995b ).
Bladder cancer
Carcinoma in situ or papillomas are presumed to give rise to transitional cell carcinoma (TCC) of the bladder.
ISH of TCC has been reported frequently. A FISH study with repetitive probes on tumor cell suspensions showed monosomy for chromosome 9 as the most frequently occurring abnormality, followed by trisomy for chromosomes 1, 7, and 11 (Hopman et al. 1991) . The data suggested that loss of chromosome 9 may be an early event in the development of bladder cancer, while aberrations involving chromosomes 1 and 7 may be important in tumor progression. Waldman et al. (1991) demonstrated in a FISH study on touch preparations of TCCs, monosomy of chromosome 9, as well as overrepresentation of chromosomes 7 and 11. Matsuyama et al. (1994b) performed double-target ISH on 37 cases of bladder cancer. Trisomy 7, monosomy 9, and trisomy 10 were detected most frequently. In a study by Poddighe et al. (1992) , structural aberrations of chromosome 1 were examined in nuclear suspensions of TCC by FISH with a combination of centromeric (1q12), telomeric (1p36), and library DNA probes. Meloni et al. (1993) demonstrated that FISH analysis on urine and bladder washings is a very useful tool in the diagnosis, early detection, and clinical management of bladder cancer. Sauter et al. (1993) showed heterogeneity in amplification of the erbB-2 oncogene in a small number of cases by dual-labelling FISH with a centromeric probe for chromosome 17 and a cosmid probe for the erbB-2 locus. The suitability of both conventional karyotyping and FISH in the detection of intratumoral heterogeneity in bladder cancers was investigated by Schapers et al. (1993) . More recently, Sauter et al. (1994) examined single-cell suspensions from 106 formalin-fixed bladder cancers, as well as touch imprints of 45 fresh bladder tumors, by FISH with probes for the centromeric region of chromosome 17 and a cosmid for the p53 locus on 17p13.1. Double-hybridization experiments showed an increment in the percentage of 17p deletions with advancing tumor stage. Deletion of 17p was also highly correlated with tumor grade and with p53 immunostaining. Similarly, FISH with a p53-specific probe was applied to cell suspensions of a panel of 42 TCCs by Matsuyama et al. (1994c) . In 64% of the specimens, p53 deletion was seen, whereas 38% showed overexpression at the immunohistochemical level.
A CGH study of 26 mainly high-grade, high-stage TCCs by Kallioniemi et al. (1995) showed losses affecting chromosomes 3p, 8p, 9, 11p, 11q, 17p, and 12q. Gains of DNA sequences were most often found at chromosomal regions distinct from locations of currently known oncogenes. Additionally, a CGH study of 14 lowand high-grade/stage TCCs (Voorter et al. 1995) revealed other regions of amplification. Imbalances involved losses of chromosomes 5, 9, and 11. In half of the cases, loss detected by CGH was also detected by RFLP studies.
Kidney cancer
Renal cell carcinomas (RCCs) are, in general, adenocarcinomas. FISH has been performed with yeast artificial v chromosomes to identify the position of translocation breakpoints (t3;6) and t(3;8) in familial RCC by a number of groups (e.g., Wilke et al. 1994) . A FISH study on a small panel of disaggregated archival RCC tissue specimens showed numerical aberrations of chromosomes 1, 7, 17, and Y (Wolman et al. 1993) . Abnormal copy numbers of chromosomes 1 and/or 17 in seven out of nine cases had not been identified by previous karyotyping. Beck et al. (1995) performed FISH on single-cell suspensions of 37 RCCs. Numerical aberrations of chromosomes 1 and/or chromosome 7 were present in 18 RCCs, and five of these cases showed monosomy for chromosome 1 in more than 50% of the tumor cells. Section ISH using a large probe set showed that chromosomes 1, 3, 7, and 17 have a higher propensity for aneuploidy than chromosomes 8, 10, 11, 12, and 16 (El-Naggar et al. 1994 ). Further, these results correlated with DNA flow cytometry. CGH in chromophobe RCC, a subtype of RCC, showed specific loss of chromosomes 1, 2, 6, 10, 13, 17, and 21 . found a correlation of genetic changes with clinical outcome. Losses were most prevalent at 3p, 9p, and 13q. Gains were most frequently seen of 5q and 7. The same group found a high degree of concordance between CGH and allelotyping . Recently, the involvement of 1q gain and 3p loss in metastatic tumor progression was described (Gronwald et al. 1997 ).
Breast cancer
Breast cancer comprises ductal and lobular adenocarcinomas, each having a specific precancerous defect, i.e., ductal (DCIS) and lobular carcinoma in situ (LCIS). A considerable number of ISH studies has been published, most often on ductal-type breast carcinoma. Devilee et al. (1988) showed numerical aberrations of chromosome 1 and/or 18 in six out of seven primary breast tumors by performing FISH with centromeric probes. Matsumura et al. (1992) visualized only one copy of a 17p13.1 cosmid DNA probe in nuclei with loss of heterozygosity (LOH) at the 17p13.3 region, whereas nuclei without LOH at that locus showed no deletions by FISH. Microdissection followed by FISH was used to identify chromosomal HSRs (Meltzer et al. 1992; Guan et al. 1994) . The results indicated amplification of regions 17q12 (erbB-2 region), 13q21, and 20q12-13.2. Balazs et al. (1995) investigated karyotypic heterogeneity in touch preparations of 23 breast cancers by FISH. Every tumor analyzed showed a heterogenous distribution for at least one chromosome. Micale et al. (1994) revealed gain of chromosome 1 by FISH applied to tissue sections of breast cancers and hyperplastic lesions. Interestingly, aneuploidy for several chromosomes was also seen in the hyperplastic tissue. FISH with a chromosome 17 centromeric probe showed polysomy of chromosome 17 in non-invasive DCIS (Murphy et al. 1995) . Further, erbB-2 amplification was seen in both the invasive and non-invasive components within a breast cancer biopsy. Recently, chromosome 1 aneusomy was identified on archival tissue sections of 16 DCISs (Harrison et al. 1995) . The authors concluded that chromosome 1 aneusomy precedes invasion and that it is a relatively consistent occurrence in high-grade lesions.
CGH applied to 15 breast cancer cell lines and 33 primary tumors showed increased DNA sequences in twothirds of primary tumors and almost all cell lines . Most of these amplified loci were distinct from those of currently known amplified genes in breast cancer, with sequences originating from 17q22-q24 and 20q13 displaying the highest frequency of amplification. Several amplifications, including the ones described above, were observed by Muleris et al. (1994) . A study by Ried et al. (1995) showed copy number increases of chromosome 1q and 8q sequences. Loss was seen for chromosome 17p and 22. Interestingly, Isola et al. (1995) demonstrated that increased copy numbers of chromosomes 8q and 20q13 correlated with recurrence rate in node-negative breast cancer and therefore may confer a more aggressive phenotype. Recently, CGH of DCIS revealed gains of 1q, 17q, 19q, and 20q, losses were seen of 13q, 14q, 16q, 17p, and 22q (James et al. 1997) . Chromosomal alterations appeared more frequently in higher grades of DCIS.
Ovarian cancer
Ovarian carcinomas represent a heterogeneous group of tumors, most of them being papillary adenocarcinomas. A recent interphase cytogenetics study by Liehr et al. (1994) revealed specific loss of chromosomes 17 and 20, and gain of chromosomes 1, 7, 8, and 11. Persons et al. (1993) performed FISH with centromeric probes to touch preparations of 25 epithelial ovarian tumors. They showed relative loss of chromosomes 17 and X, as well as a relative gain of chromosomes 12 and 8. Additionally, they showed the HER-2/neu gene to be amplified in 2 of the 25 tumors. Chromosome microdissection followed by FISH was used to identify the chromosomal origin of amplified regions in HSRs of seven ovarian carcinomas (Guan et al. 1995) . The results showed that 12 specific chromosome regions are amplified, including 11q, 12q, 16p, 19p, and 19q . These regions may harbor genes important in ovarian cancer tumorigenesis. Recently, gains of chromosomes 6 and 7 were seen in borderline tumors, a presumed precursor condition of ovarian carcinoma (Diebold et al. 1996) . CGH of invasive ovarian cancers revealed, most importantly, gain of 3q and 8q sequences, loss was found most frequently of 16q and 17 (Iwabuchi et al. 1995) . The overall concordance between concurrently performed LOH and reduced copy number by CGH was 84%.
Discussion and conclusion
It can be stated that interphase hybridization technology has emerged as an important instrument for the delinea-tion of genetic changes in human solid cancers. Results from molecular and karyotyping studies could be confirmed in situ and, in addition, new genetic aberrations are being disclosed. For example, in lung cancer (NSCLC), FISH with region-specific probes showed loss of the p15/p16 region at 9p, which is consistent with LOH studies. In head and neck tumors (HNSCC), CGH studies repeatedly identified a new amplified chromosomal region, 3q26-qter. This region has not been described before, and may harbor a new oncogene important in HNSCC development. ISH on colon cancer specimens has confirmed the presence of numerical and structural aberrations frequently encountered in colorectal tumors, such as trisomy 7 and monosomy 18. It has also added some new numerical aberrations, e.g., gain of chromosome 12. Additionally, CGH of adenomas revealed gains of chromosome 7 and 20. In prostatic adenocarcinoma, ISH analyses have confirmed chromosomal abnormalities that had been previously detected by karyotyping and LOH studies. However, they appear at much higher frequency than was previously suspected from conventional cytogenetic analysis (e.g., loss of Y and alterations of chromosome 8). Additionally, ISH analysis rendered possible markers for the biological aggressiveness of prostatic tumors, such as gain of chromosomes 7 and 8. CGH also provided some new regions of interest, most notably the amplification of the 8q arm. This is, most likely, the result of isochromosome 8q formation, which is illustrated by a combined ISH/CGH effort in Figs. 1 and 2 . In bladder cancer, CGH studies have confirmed some sites of allelic loss, as, for instance, loss of 11p, and have added some interesting new chromosomal regions of amplification. FISH studies of breast cancers with region-specific probes for the 17p13.1 (p53) region and the 13q14 (Rb) region were in concordance with LOH studies. FISH was also used to identify the origin of HSRs, a frequently seen abnormality in this type of cancer. One of the amplified oncogenes is the erbB-2 gene on 17q12. Another, yet unknown, resides in the 20q12-13 region, a site that was revealed by CGH analysis. The latter technique also distinguished frequent alterations in DCIS, the precursor of invasive ductal carcinoma.
In conclusion, ISH and CGH have established their importance in solid cancer genetics and will continue to gain momentum in this area of research. Microdissection technology (Zhuang et al. 1995) will yield further access to analysis of small tissue areas, which is especially important for CGH studies of precancerous lesions. Furthermore, the increasing and continuing availability of new types of DNA probes, such as phage and bacterial artificial chromosomes (Monaco and Larin 1994) , will facilitate the in situ detection of possibly important genetic sites. 
